EP1452179A1 — Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
Assigned to Chiesi Farmaceutici SpA · Expires 2004-09-01 · 22y expired
What this patent protects
The present invention relates to the use of a bronchodilator in combination with an anti-inflammatory corticosteroid or an anticholinergic atropine-like derivative for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), a…
USPTO Abstract
The present invention relates to the use of a bronchodilator in combination with an anti-inflammatory corticosteroid or an anticholinergic atropine-like derivative for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), and to pharmaceutical compositions containing the two active ingredients. In particular, the invention relates to the use of the long-acting β 2 -agonist 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl-2(1H)-quinolinone and/or physiologically acceptable salts and/or solvates thereof in combination with a corticosteroid.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.